News & Updates
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). SER-301 is an oral, rationally-designed microbiome therapeutic designed to dampen the aberrant gastrointestinal inflammation central to ulcerative colitis…
Read More
Excerpt from the Article: Pfizer Inc says its experimental COVID-19 vaccine is more than 90-percent effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world’s economy, and upended daily life. Pfizer and German partner BioNTech SE are the first drugmakers to release successful data…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Emulate, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration (FDA) to enable multiple studies across FDA offices in priority research areas, including programs to evaluate COVID-19 vaccines and understand human immune response against SARS-CoV-2, the…
Read More
Excerpt from the Article: LA JOLLA—As people across the world anxiously await the promise of an effective vaccine to end the coronavirus pandemic that has killed over 220,000 Americans and more than 1.1 million globally, it is important to remember a time when the world faced similar challenges and, through scientific research, found answers that…
Read More
For our Canadian clients! “Learn about the SR&ED Program and how it benefits health science companies. OBIO will have experts from the CRA to explain the eligibility criteria, what expenditures qualify, and how to file a scientific research and experimental development (SR&ED) claim for this year.” To Register Click the Button Below: Register Free!
Read More
Excerpt from the Press Release: OCEANSIDE, Calif., Oct. 29, 2020 /PRNewswire/ — Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today publication on the NIH clinical trials website1 of its newly initiated trial aiming to validate a blood-based diagnostic for predicting suicide risk. The Campbell Score™, which is a patent-pending method of quantifying inflammatory-associated biological markers,…
Read More
We are absolutely delighted with the positive engagement we’ve had from our first four Ask Us Anything in Clinical Research – Virtual Networking Meetings. It’s hard to believe we have had this many so far! Based on this success, we have decided to continue the series into 2021 with our next virtual meeting on November…
Read More
Excerpt from the Article: On a Friday afternoon in mid-March 2020, as the emergency department at Massachusetts General Hospital began admitting its first coronavirus patients, attending emergency physician and researcher Michael Filbin recognized an urgent need to quickly learn about the emerging pathogen. With a surge of COVID-19 patients expected in the hospital in the…
Read More
Excerpt from the Press Release: WOBURN, Mass.–(BUSINESS WIRE)–ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune diseases, today announced it has launched a Phase 1b study as a multiple ascending dose (MAD) trial. The study is in patients who have type 1 diabetes (T1D), an as yet incurable…
Read More
Excerpt from the Article: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. Specifically, based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommends further…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?